23.10.2023 14:51:32

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 23 October 2023 – On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023.

Under the programme initiated 10 August 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.7 billion in the period from 10 August 2023 to 31 October 2023.

Since the announcement 16 October 2023, the following transactions have been made:

 Number of B shares (of DKK 0.10)Average purchase priceTransaction value, DKK
Accumulated, last announcement6,993,162 4,548,993,033
16 October 2023145,000720.34104,449,422
17 October 2023145,000717.25104,000,773
18 October 2023135,000711.8296,095,956
19 October 2023140,000703.4098,475,655
20 October 2023145,000687.3599,665,731
Accumulated under the programme7,703,162 5,051,680,570

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 40,196,846 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares of DKK 0.10 in the company is 4,510,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 30 billion during a 12-month period beginning 1 February 2023. As of 20 October 2023, Novo Nordisk has since 1 February 2023 repurchased a total of 36,140,324 B shares of DKK 0.10 at an average share price of DKK 562.83 per B share of DKK 0.10 equal to a transaction value of DKK 20,340,911,156.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media: 
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

Elizabeth DeLuca (US)
+1 609 580 9868
edel@novonordisk.com

Investors: 
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Sina Meyer
+45 3075 6656 azey@novonordisk.com
Frederik Taylor Pitter
+45 3075 8259 fptr@novonordisk.com

Company Announcement No 66 / 2023

Attachments


Analysen zu Novo Nordiskmehr Analysen

27.11.24 Novo Nordisk Buy Deutsche Bank AG
27.11.24 Novo Nordisk Buy Goldman Sachs Group Inc.
18.11.24 Novo Nordisk Neutral UBS AG
15.11.24 Novo Nordisk Buy Goldman Sachs Group Inc.
13.11.24 Novo Nordisk Neutral UBS AG
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novo Nordisk 100,42 -0,02% Novo Nordisk